Information Provided By: 
Fly News Breaks for November 7, 2019
AERI
Nov 7, 2019 | 07:47 EDT
Oppenheimer analyst Esther Rajavelu lowered her price target for Aerie Pharmaceuticals to $25 from $45 following the Q3 results and guidance revision, saying she now models a flatter revenue curve vs. prior estimates. While management continues to improve payor coverage, Rajavelu tells investors in a research note that she believes revenue uptake could lag meaningfully, since changing prescriber habits could take longer than originally anticipated. Rajavelu keeps an Outperform rating on the shares.
News For AERI From the Last 2 Days
There are no results for your query AERI
